-

Capital Rx Named Winner of 2021 Edison Award

Company’s Clearinghouse ModelTM, Designed to Simplify Prescription Drug Pricing, Captures Silver Award

NEW YORK--(BUSINESS WIRE)--Capital Rx, the fastest-growing pharmacy benefit manager (PBM) in the U.S., announced today that its Clearinghouse ModelTM pricing framework has won a 2021 silver Edison Award. Named after Thomas Alva Edison, the Edison Awards have recognized and honored some of the most innovative new products, services, and business leaders in the world since 1987.

Capital Rx created the Clearinghouse ModelTM to lower medication costs and bring pricing transparency to patients. Abandoning the old way of pricing medications and utilizing National Average Drug Acquisition Cost (NADAC), a publicly available, government-maintained medication pricing list, it is the first major innovation in the way prescriptions are priced in over two decades. Through this new pricing framework, the company brings full visibility to drug unit prices and eliminates arbitrary price variability for patients and employers. Capital Rx has delivered 13% year-over-year trend reduction for clients on average, while deploying a range of solutions enhancing the patient and provider experience.

“We are honored to be chosen as a silver winner of the Edison Award,” said AJ Loiacono, CEO at Capital Rx. “Our Clearinghouse ModelTM democratizes price and removes artificial price variability, ensuring everyone gets the same price and eliminating a troubling legacy of traditional PBMs benefiting off patients.”

The Clearinghouse ModelTM pricing framework was chosen by a panel of judges comprised of more than 3,000 senior business executives and academics.

“We were very impressed by the level of collaboration and discovery in this year’s entries,” said Edison Universe Executive Director Frank Bonafilia. “Somehow, while facing the unprecedented challenges of this global pandemic, companies around the world figured out how to work safely and smartly and still innovate at an award-winning level.”

For more information on Capital Rx’s Clearinghouse ModelTM, visit www.Cap-Rx.com.

About Capital Rx

Capital Rx is a health technology company that is leading the transformation of the pharmacy benefits industry. Capital Rx’s enterprise pharmacy platform, JUDITM, digitally links providers, patients, pharmacies, and plans to achieve the highest standard of clinical care. By establishing a competitive marketplace through its Clearinghouse ModelTM, Capital Rx unlocks the pharmacy supply chain to ensure patients receive seamless access to medication at the lowest price.

Contacts

Capital Rx:
Genevieve Pasculli
Capital Rx
Phone: +1.646.878.6902
gpasculli@cap-rx.com

Media:
Alexis Feinberg
Westwicke/ICR PR
Phone: +1 203.939.2225
Alexis.Feinberg@westwicke.com

Capital Rx


Release Versions

Contacts

Capital Rx:
Genevieve Pasculli
Capital Rx
Phone: +1.646.878.6902
gpasculli@cap-rx.com

Media:
Alexis Feinberg
Westwicke/ICR PR
Phone: +1 203.939.2225
Alexis.Feinberg@westwicke.com

More News From Capital Rx

Capital Rx and 3 Axis Advisors Study Finds Potential for Billions in Prescription Drug Savings With Transparent Pricing Practices

NEW YORK--(BUSINESS WIRE)--Capital Rx, the fastest-growing pharmacy benefit manager in the U.S., announced today the results of a study that it commissioned with 3 Axis Advisors, which found that implementing transparent pricing practices via the National Average Drug Acquisition Cost (NADAC) benchmark has the potential to create billions of dollars in savings, and restore public trust in the U.S. drug pricing system. The full study results are available here. Potential legislative changes coul...

Capital Rx Crushes Net Promoter Score® and Receives 100 Percent-Positive Feedback on Client Implementation Satisfaction

NEW YORK--(BUSINESS WIRE)--Capital Rx announces a year-over-year increase in its Client NPS® from 2019 to 2020, and 100% positive feedback from new clients for 2021....

Capital Rx Secures $50 Million in Series B Financing to Accelerate Growth of Pharmacy Technology Platform

NEW YORK--(BUSINESS WIRE)--Capital Rx, the fastest-growing pharmacy benefit manager in the U.S., announced today that it has raised $50 million in Series B financing. The funding round is led by Transformation Capital, with participation from Edison Partners, who led Capital Rx’s Series A financing in 2019. “Capital Rx started its mission three years ago to change the way prescriptions are priced and serviced to create enduring social change,” said AJ Loiacono, CEO at Capital Rx. “With this cap...
Back to Newsroom